Q-omics provides the consensus-scored CSNK1A1P1 profile across patient tissues and cancer cell-line models. CSNK1A1P1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CSNK1A1P1 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, CSNK1A1P1 RNA expression shows 16,073 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, KIRC, and TGCT as cancer lineages where CSNK1A1P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CSNK1A1P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CSNK1A1P1 survival associations across molecular data types. CSNK1A1P1 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CSNK1A1P1 RNA expression–survival associations across cancer types. High CSNK1A1P1 expression shows unfavorable associations in LGG and KIRP, but favorable associations in HNSC, LIHC, GBM and OV. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for CSNK1A1P1 RNA expression.
This table summarizes CSNK1A1P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CSNK1A1P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CSNK1A1P1 shows lower tumor expression in KIRC, KIRP, KICH and THCA and higher tumor expression in COAD and LUSC. The KIRC box plot shows higher CSNK1A1P1 RNA expression in normal versus tumor tissue (log2 FC = −0.137, t-test p < 0.001).
This table shows molecular features associated with CSNK1A1P1 in patient tissues and cancer cell lines. In patient samples, CSNK1A1P1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
